Immatics Biotechnologies GmbH announced today that it has entered into a research collaboration and license agreement with Genmab A/S (Nasdaq Copenhagen: GEN) to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.
Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies
Immatics Appoints Stephen Eck as Chief Medical Officer US
Immatics, a leading company in the field of cancer immunotherapy, today announced the appointment of Stephen Eck, M.D., Ph.D. as Chief Medical Officer (CMO) at Immatics US, Inc. (Houston, Texas), effective immediately.
Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing
Crescendo Biologics Ltd (Crescendo), announced today that it has completed a $70 million (€57 million) Series B financing.
The funds will be used to advance the development of its lead programme, CB307, which stimulates local activation of tumour-specific T-cells, into the clinic and further expand its internal pipeline of products.